Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.32 | -$0.10 | -$0.19 |
| Q2 2025 | 1 | -$0.27 | -$0.09 | -$0.16 |
| Q3 2025 | 1 | -$0.25 | -$0.08 | -$0.15 |
| Q4 2025 | 1 | -$0.22 | -$0.07 | -$0.13 |
| Q1 2026 | 1 | -$0.20 | -$0.07 | -$0.12 |
| Q2 2026 | 1 | -$0.19 | -$0.06 | -$0.12 |
| Q3 2026 | 1 | -$0.18 | -$0.06 | -$0.11 |
| Q4 2026 | 1 | -$0.17 | -$0.06 | -$0.10 |
| Q1 2027 | 1 | -$0.01 | -$0.00 | -$0.00 |
| Q2 2027 | 1 | $0.01 | $0.02 | $0.01 |
| Q3 2027 | 1 | $0.01 | $0.04 | $0.02 |
| Q4 2027 | 1 | $0.02 | $0.05 | $0.03 |
| Q1 2028 | 1 | $0.28 | $0.83 | $0.50 |
| Q2 2028 | 1 | $0.29 | $0.87 | $0.53 |
| Q3 2028 | 1 | $0.28 | $0.85 | $0.51 |
| Q4 2028 | 1 | $0.28 | $0.86 | $0.52 |
Humacyte, Inc. last posted its earnings results on Wednesday, November 12th, 2025. The company reported $-0.1106 earnings per share for the quarter, topping analysts' consensus estimates of $-0.15104 by $0.04044. The company had revenue of 753.00 K for the quarter and had revenue of 0 for the year. Humacyte, Inc. has generated $-1 earnings per share over the last year ($-1.26 diluted earnings per share) and currently has a price-to-earnings ratio of -10.5. Humacyte, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 7th, 2025 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2025 | Q3 2025 | -$0.15 | -$0.11 | 0.04 | $922.83 K | $753.00 K |
| 08/11/2025 | Q2 2025 | -$0.16 | -$0.24 | -0.08 | $1.00 M | $301.00 K |
| 05/13/2025 | Q1 2025 | -$0.19 | $0.28 | 0.47 | N/A | $517.00 K |
| 03/31/2025 | Q4 2024 | N/A | -$0.16 | N/A | N/A | $7.23 M |
| 11/08/2024 | Q3 2024 | N/A | -$0.33 | N/A | N/A | $0 |
| 08/13/2024 | Q2 2024 | N/A | -$0.48 | N/A | N/A | $0 |
| 05/13/2024 | Q1 2024 | N/A | -$0.29 | N/A | N/A | $0 |
| 03/28/2024 | Q4 2023 | N/A | -$0.24 | N/A | N/A | $0 |
| 11/09/2023 | Q3 2023 | N/A | -$0.25 | N/A | $66.67 K | $0 |
| 08/14/2023 | Q2 2023 | N/A | -$0.22 | N/A | $66.67 K | $0 |
| 05/12/2023 | Q1 2023 | N/A | -$0.60 | N/A | N/A | $0 |
| 03/24/2023 | Q4 2022 | N/A | $0.13 | N/A | N/A | $0 |
| 11/10/2022 | Q3 2022 | N/A | -$0.25 | N/A | N/A | $31.00 K |
| 08/12/2022 | Q2 2022 | N/A | $0.36 | N/A | N/A | $1.30 M |
| 05/13/2022 | Q1 2022 | N/A | -$0.16 | N/A | N/A | $233.00 K |
| 03/29/2022 | Q4 2021 | N/A | $0.41 | N/A | N/A | $177.00 K |
| 11/12/2021 | Q3 2021 | N/A | -$0.72 | N/A | N/A | $241.00 K |
| 08/16/2021 | Q2 2021 | N/A | -$0.17 | N/A | N/A | $690.00 K |
| 05/17/2021 | Q1 2021 | N/A | -$0.20 | N/A | N/A | $155.00 K |
| 02/16/2021 | Q4 2020 | N/A | -$5.61 | N/A | N/A | $124.00 K |
Humacyte, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 7th, 2025 based offlast year's report dates.
In the previous quarter, Humacyte, Inc. (:HUMAW) reported $-0.1106 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.15104 by $0.04044.
The conference call for Humacyte, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Humacyte, Inc.'s latest earnings report can be read online.
Humacyte, Inc. (:HUMAW) has a recorded net income of $-148,701,000.Humacyte, Inc. has generated $-1.26 earnings per share over the last four quarters.
Humacyte, Inc. (:HUMAW) has a price-to-earnings ratio of -10.5 and price/earnings-to-growth ratio is -0.21.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED